Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Advancements in next-generation sequencing technologies, increasing adoption of precision oncology, and rising cancer incidence worldwide are driving the genomics in cancer care market growth.Austin, ...